Literature DB >> 7197565

A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations.

M A Flaum, R T Schooley, A S Fauci, H R Gralnick.   

Abstract

A retrospective blind study of 32 patients with the hypereosinophilic syndrome was undertaken utilizing a hematologic scoring system that was based on peripheral blood and bone marrow findings, cytogenetics B12 levels, and leukocyte alkaline phosphatase determinations. In addition to the grading system, which allowed formulation of a hematologic score, the date could also be normalized for individuals who did not have all tests performed by use of the hematologic quotient. This study clearly defined two groups of patients within the idiopathic hypereosinophilic syndrome. One group were those individuals with low hematologic scores and quotients who did not require therapy or who responded to prednisone therapy, while the second group of patients required cytotoxic therapy. These patients had significantly higher hematologic scores and quotients and a significant number of abnormalities similar to those seen in myeloproliferative syndromes, such as myelofibrosis and cytogenetic abnormalities. This type of hematologic scoring seems useful in predicting therapy and/or evaluating individuals or groups of patients with the hypereosinophilic syndrome.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7197565

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  Eosinophilic myeloproliferative disorders.

Authors:  Amy D Klion
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  New properties and roles for eosinophils in disease: discussion paper.

Authors:  C J Spry
Journal:  J R Soc Med       Date:  1985-10       Impact factor: 5.344

3.  Pathology of a new toxic syndrome caused by ingestion of adulterated oil in Spain.

Authors:  F J Martinez-Tello; J J Navas-Palacios; J R Ricoy; R Gil-Martín; J M Conde-Zurita; F Colina-Ruiz Delgado; I Tellez; A Cabello; S Madero-García
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

4.  Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients: absence of detectable receptor correlates with resistance to corticotherapy.

Authors:  L Prin; P Lefebvre; V Gruart; M Capron; L Storme; P Formstecher; S Loiseau; A Capron
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

5.  Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified.

Authors:  Sa A Wang; Wayne Tam; Albert G Tsai; Daniel A Arber; Robert P Hasserjian; Julia T Geyer; Tracy I George; David R Czuchlewski; Kathryn Foucar; Heesun J Rogers; Eric D Hsi; B Bryan Rea; Adam Bagg; Paola Dal Cin; Chong Zhao; Todd W Kelley; Srdan Verstovsek; Carlos Bueso-Ramos; Attilio Orazi
Journal:  Mod Pathol       Date:  2016-05-13       Impact factor: 7.842

Review 6.  Clinical overview of cutaneous features in hypereosinophilic syndrome.

Authors:  Sabine Gisela Plötz; Bettina Hüttig; Birgit Aigner; Christian Merkel; Knut Brockow; Cezmi Akdis; Ulf Darsow; Johannes Ring
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

7.  Plasma membrane antigens on light density and activated human blood eosinophils.

Authors:  P C Tai; D M Bakes; J R Barkans; C J Spry
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

8.  Cyclosporin for hypereosinophilic syndrome.

Authors:  P Zabel; M Schlaak
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

9.  Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.

Authors:  D Tan; W Hwang; H J Ng; Y T Goh; P Tan
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

Review 10.  Hypereosinophilic Syndrome.

Authors:  Casey Curtis; Princess Ogbogu
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 10.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.